Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

HBW Insight

With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives

By Malcolm Spicer 07 Mar 2019

Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.

Topic FDA

View article
Scrip

Bayer Bosses Beg Risk-Averse Europe To Rethink

By Kevin Grogan 07 Mar 2019

The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

Topic Cell and gene therapy

View article
Scrip

Asia Deal Watch: Bharat Expands Its Vaccine Holdings By Buying GSKs Chiron Behring

By Anju Ghangurde 07 Mar 2019

Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.

Topic Drug approval Business strategies

View article
HBW Insight

Targeted Omega-3 Supplementation Could Save Up To €64.5bn In Healthcare Costs, Food Supplements Europe Claims

By David Ridley 07 Mar 2019

A new position paper by Food Supplements Europe calculates the potential savings that targeted supplementation with omega-3, calcium, phytosterols and vitamins D and B9 could bring for cash-strapped European governments.

Topic Drug development landscape Drug review

View article
Generics Bulletin

Two New Categories Join GGB Awards In 2019

By David Wallace 07 Mar 2019

Two new categories – Value Added Medicine Of The Year and Legal Strategy Of The Year – have been added to the Global Generics & Biosimilars Awards in 2019, which will take place on 5 November in Frankfurt, Germany.

Topic BioPharmaceutical Biosimilars

View article
Generics Bulletin

US Bill Aims To Increase Transparency On Biologics

By David Wallace 07 Mar 2019

Several US senators have lent their backing to the draft Biologic Patent Transparency Act, as part of efforts to address “patent thickets” around brand biologics.

Topic BioPharmaceutical Drug approval Drug review

View article
Datamonitor Healthcare, Biomedtracker

Q1 Outlook Webinar: Key Catalysts and their Impact on Pharma Markets

By Michael Haydock 04 Mar 2019

Find out which market-moving events and catalysts to watch for during the Q1 Outlook Webinar - Key catalysts and their impact on pharma markets.

Topic Drug approval Drug development landscape Drug review

Full video
HBW Insight

E-Cigarettes' Appeal For Smoking Cessation Cooled By Risk Questions

By Eileen Francis 27 Feb 2019

E-cigarette use among people with cancer increased from 8.5% in 2014 to 10.7% in 2017, with the greatest increase among people younger than 50, according to a JAMA Oncology study. A recently NEJM study also questions safety of growing dependence on e-cigarettes by people trying to quit smoking.

Topic Cancer

View article
Scrip

Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore

By Ian Haydock 27 Feb 2019

Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.

Topic Research

View article
Scrip

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

By Jessica Merrill 27 Feb 2019

Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.

Topic Drug review

View article
Pink Sheet

How can you capture the attention of highly-engaged decision-makers in biopharma?

22 Feb 2019

By partnering with the Pink Sheet. Pink Sheet is the world’s premier provider of compliance, legislation, policy regulation and industry developments for biopharma decision makers, arming subscribers with the critical information they rely on daily to implement their strategies.

Topic BioPharmaceutical

View infographic
Pink Sheet

Latin America Inches Towards Greater Regulatory Harmonization

By Francesca Bruce 22 Feb 2019

Regulatory harmonization is gathering pace in Latin America, which is good news for pharmaceutical companies.

Topic Policy and regulation

View article
Scrip

Mortality Signal For Pfizers Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class

By Emily Hayes 21 Feb 2019

Analyst speculates that risk of pulmonary embolism for a higher unapproved of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.

Topic Arthritis

View article
Scrip

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

By Kevin Grogan 21 Feb 2019

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.

View article
Scrip, Pink Sheet

Webinar: What’s the Reality of Real World Evidence?

By Mary Jo Laffler 19 Feb 2019

The data and analysis for this webinar were drawn from Pink Sheet and Scrip, both part of the Informa Pharma Intelligence suite of intelligence solutions.

Full video

Latest headlines

Pink Sheet

19 Mar 2019

‘Keep Planning For No-Deal Brexit,’ UK Govt Tells Pharma As Chaos Grows

Link
Scrip

19 Mar 2019

Zulresso Is Sage’s First Step In Postpartum Depression Treatment

Link
Scrip

19 Mar 2019

Merck KGaA Interview: China E-Health Push A ‘Long-Term Strategy’

Link
Pink Sheet

19 Mar 2019

US FDA “Enriches” Trial Guidance With Recent Examples

Link
Scrip

19 Mar 2019

PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate

Link
Pink Sheet

19 Mar 2019

AbbVie's 'Unjustified' Humira Settlements Divide Market, Class Action Claims

Link
Pink Sheet

19 Mar 2019

Gottlieb Touts US FDA's Organizational Structure For Advancing Policies During His Tenure

Link
Scrip

19 Mar 2019

Urovant’s Vibegron Faces Tough Commercial Climb Despite Phase III Success

Link
Pink Sheet

19 Mar 2019

Clinical Trials: US FDA Should Frame Risk-Based Monitoring As Best Practice, ACRO Says

Link
Pink Sheet

19 Mar 2019

Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock

Link
Pink Sheet

19 Mar 2019

FDA Inspectors Focusing Attention On Traditional Manual Aseptic Filling Lines

Link
Pink Sheet

19 Mar 2019

Proponents Of Quality Control Multi-Attribute Methods Tackle Adoption Challenges

Link
Scrip

19 Mar 2019

TIME-2b Disappointed: Aerpio’s Lead Product Fails In Diabetic Retinopathy

Link
Scrip

19 Mar 2019

Abbott Builds Its Digital Reach In India

Link
Pink Sheet

18 Mar 2019

Italy Moves To Raise Biosimilar Use And Awareness

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Pharmaceutical intelligence for consultancies

Your trusted pharma partner

Our unique strengths

Understand your clients’ world

Stay on top of the details

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product List

Thought leadership

Awareness

Lead generation

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store